Symbols / SABS
SABS Chart
About
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 178.05M |
| Enterprise Value | 73.36M | Income | -4.29M | Sales | 114.70K |
| Book/sh | 3.48 | Cash/sh | 2.33 | Dividend Yield | — |
| Payout | 0.00% | Employees | 63 | IPO | — |
| P/E | — | Forward P/E | -12.47 | PEG | — |
| P/S | 1552.33 | P/B | 1.08 | P/C | — |
| EV/EBITDA | -1.83 | EV/Sales | 639.56 | Quick Ratio | 10.32 |
| Current Ratio | 10.49 | Debt/Eq | 3.75 | LT Debt/Eq | — |
| EPS (ttm) | -1.56 | EPS next Y | -0.30 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 06:00 | ROA | -22.76% |
| ROE | 18.56% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -376.57% | Profit Margin | 163.38% | Shs Outstand | 47.61M |
| Shs Float | 19.12M | Short Float | 4.26% | Short Ratio | 4.50 |
| Short Interest | — | 52W High | 6.60 | 52W Low | 1.00 |
| Beta | 0.60 | Avg Volume | 351.22K | Volume | 578.00K |
| Target Price | $9.38 | Recom | None | Prev Close | $3.67 |
| Price | $3.74 | Change | 1.91% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.38
Mean price target
2. Current target
$3.74
Latest analyst target
3. DCF / Fair value
$-7.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.74
Low
$5.00
High
$15.00
Mean
$9.38
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-07 | init | UBS | — → Buy | $7 |
| 2025-12-19 | init | Guggenheim | — → Buy | $15 |
| 2025-12-18 | main | Chardan Capital | Buy → Buy | $12 |
| 2025-11-17 | main | Chardan Capital | Buy → Buy | $12 |
| 2025-09-19 | main | Chardan Capital | Buy → Buy | $12 |
| 2025-09-17 | init | Leerink Partners | — → Outperform | $7 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $12 |
| 2025-07-22 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-05-15 | main | Chardan Capital | Buy → Buy | $20 |
| 2025-04-01 | main | Chardan Capital | Buy → Buy | $20 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-01-29 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-01-29 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-11-07 | main | Chardan Capital | Buy → Buy | $25 |
| 2024-10-09 | init | Craig-Hallum | — → Buy | $11 |
| 2024-09-12 | reit | Oppenheimer | Outperform → Outperform | $12 |
| 2024-09-09 | main | Chardan Capital | Buy → Buy | $25 |
| 2024-08-28 | init | Oppenheimer | — → Outperform | $12 |
| 2024-08-12 | main | Chardan Capital | Buy → Buy | $25 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
- SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners are individual investors who got richer after stock soared 22% last week - Yahoo Finance Sat, 22 Nov 2025 08
- SAB BIO Secures $175M Funding Led by Sanofi to Advance Revolutionary Type 1 Diabetes Treatment Through 2028 - Stock Titan Mon, 21 Jul 2025 07
- We Think SAB Biotherapeutics (NASDAQ:SABS) Can Afford To Drive Business Growth - simplywall.st Sat, 22 Nov 2025 08
- SAB Biotherapeutics, Inc. Management to Participate in February Investor Conferences - Quiver Quantitative Wed, 04 Feb 2026 08
- SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewswire Wed, 04 Feb 2026 08
- Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential - Investing.com Fri, 19 Dec 2025 08
- SAB Biotherapeutics Secures $175M in Private Placement - TipRanks Mon, 21 Jul 2025 07
- How SABS stock reacts to job market data - July 2025 Catalysts & High Conviction Buy Zone Picks - mfd.ru Fri, 20 Feb 2026 15
- SAB BIO Stock Explodes 54% on Game-Changing $175 Million Private Placement Deal - RagingBull Mon, 21 Jul 2025 07
- SAB Biotherapeutics Establishes New At-the-Market Offering Program - TradingView Mon, 29 Dec 2025 08
- SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance hu, 07 Aug 2025 07
- Two veteran drug leaders join the board behind a new Type 1 diabetes therapy - Stock Titan Wed, 07 Jan 2026 08
- SAB Biotherapeutics stock price target raised to $14 from $12 at Oppenheimer - Investing.com Mon, 21 Jul 2025 07
- SAB Biotherapeutics Initiates Phase 2b SAFEGUARD Trial for SAB-142 in Autoimmune Type 1 Diabetes Patients - Quiver Quantitative hu, 13 Nov 2025 08
- Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks - TipRanks Sat, 24 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1740000 | 3045000 | — | Conversion of Exercise of derivative security at price 1.75 per share. | SESSA CAPITAL MASTER, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-29 00:00:00 | I |
| 1 | 1740000 | 3045000 | — | Conversion of Exercise of derivative security at price 1.75 per share. | MOIN ANDREW D. | Director | — | 2025-09-29 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 2.18M | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.00 |
| NormalizedEBITDA | -34.38M | -33.31M | -25.52M | -11.71M |
| TotalUnusualItems | 5.39M | -4.82M | 10.40M | -3.49M |
| TotalUnusualItemsExcludingGoodwill | 5.39M | -4.82M | 10.40M | -3.49M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -34.11M | -42.19M | -18.74M | -17.14M |
| ReconciledDepreciation | 4.79M | 3.75M | 3.29M | 1.65M |
| EBITDA | -28.99M | -38.13M | -15.12M | -15.20M |
| EBIT | -33.79M | -41.88M | -18.41M | -16.85M |
| NetInterestIncome | 967.60K | 269.68K | -230.51K | -271.34K |
| InterestExpense | 318.40K | 315.28K | 301.58K | 294.46K |
| InterestIncome | 1.29M | 584.97K | 71.07K | 23.11K |
| NormalizedIncome | -39.49M | -37.37M | -26.96M | -13.66M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -34.11M | -42.19M | -18.74M | -17.14M |
| TotalExpenses | 42.91M | 38.08M | 28.92M | 13.39M |
| TotalOperatingIncomeAsReported | -42.91M | -38.08M | -28.92M | -13.39M |
| DilutedAverageShares | 9.26M | 5.52M | 4.35M | 2.73M |
| BasicAverageShares | 9.26M | 5.52M | 4.35M | 2.73M |
| DilutedEPS | -3.68 | -7.64 | -4.31 | -6.30 |
| BasicEPS | -3.68 | -7.64 | -4.31 | -6.30 |
| DilutedNIAvailtoComStockholders | -34.11M | -42.19M | -18.74M | -17.14M |
| NetIncomeCommonStockholders | -34.11M | -42.19M | -18.74M | -17.14M |
| NetIncome | -34.11M | -42.19M | -18.74M | -17.14M |
| NetIncomeIncludingNoncontrollingInterests | -34.11M | -42.19M | -18.74M | -17.14M |
| NetIncomeContinuousOperations | -34.11M | -42.19M | -18.74M | -17.14M |
| TaxProvision | 0.00 | 25.63K | 0.00 | |
| PretaxIncome | -34.11M | -42.19M | -18.72M | -17.14M |
| OtherIncomeExpense | 7.84M | -4.39M | 10.43M | -3.48M |
| OtherNonOperatingIncomeExpenses | 2.45M | 435.09K | 33.75K | 5.49K |
| SpecialIncomeCharges | 0.00 | 665.60K | ||
| OtherSpecialCharges | -665.60K | |||
| GainOnSaleOfSecurity | 5.39M | -4.82M | 10.40M | -4.15M |
| NetNonOperatingInterestIncomeExpense | 967.60K | 269.68K | -230.51K | -271.34K |
| InterestExpenseNonOperating | 318.40K | 315.28K | 301.58K | 294.46K |
| InterestIncomeNonOperating | 1.29M | 584.97K | 71.07K | 23.11K |
| OperatingIncome | -42.91M | -38.08M | -28.92M | -13.39M |
| OperatingExpense | 42.91M | 38.08M | 28.92M | 13.39M |
| OtherOperatingExpenses | -1.32M | -2.24M | -23.90M | -60.88M |
| ResearchAndDevelopment | 30.25M | 16.52M | 36.44M | 57.18M |
| SellingGeneralAndAdministration | 13.98M | 23.80M | 16.38M | 17.09M |
| GeneralAndAdministrativeExpense | 13.98M | 23.80M | 16.38M | 17.09M |
| OtherGandA | 13.98M | 23.80M | 16.38M | 17.09M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 54.66K | 54.66K | 54.66K | |
| OrdinarySharesNumber | 9.29M | 9.23M | 5.04M | 4.35M |
| ShareIssued | 9.34M | 9.28M | 5.09M | 4.35M |
| TotalDebt | 4.67M | 5.91M | 5.93M | 8.52M |
| TangibleBookValue | 25.97M | 57.30M | 31.06M | 38.55M |
| InvestedCapital | 26.25M | 58.35M | 32.37M | 40.35M |
| WorkingCapital | 15.81M | 48.09M | 7.10M | 23.74M |
| NetTangibleAssets | 25.97M | 57.30M | 31.06M | 38.55M |
| CapitalLeaseObligations | 4.39M | 4.86M | 4.61M | 6.72M |
| CommonStockEquity | 25.97M | 57.30M | 31.06M | 38.55M |
| PreferredStockEquity | 5.00 | 5.00 | ||
| TotalCapitalization | 25.97M | 57.30M | 31.60M | 38.55M |
| TotalEquityGrossMinorityInterest | 25.97M | 57.30M | 31.06M | 38.55M |
| StockholdersEquity | 25.97M | 57.30M | 31.06M | 38.55M |
| GainsLossesNotAffectingRetainedEarnings | -135.41K | 26.42K | 0.00 | |
| OtherEquityAdjustments | -135.41K | 26.42K | ||
| TreasuryStock | 5.52M | 5.52M | 5.52M | 0.00 |
| RetainedEarnings | -124.17M | -90.06M | -47.87M | -29.13M |
| AdditionalPaidInCapital | 155.79M | 152.86M | 84.45M | 67.67M |
| CapitalStock | 940.00 | 934.00 | 510.00 | 4.35K |
| CommonStock | 935.00 | 929.00 | 510.00 | 4.35K |
| PreferredStock | 5.00 | 5.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 18.23M | 26.64M | 19.85M | 42.59M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.25M | 15.83M | 4.85M | 16.14M |
| DerivativeProductLiabilities | 6.39M | 11.77M | 320.93K | 10.72M |
| LongTermDebtAndCapitalLeaseObligation | 3.86M | 4.05M | 4.53M | 5.42M |
| LongTermCapitalLeaseObligation | 3.86M | 4.05M | 3.99M | 5.42M |
| LongTermDebt | 541.64K | |||
| CurrentLiabilities | 7.98M | 10.81M | 14.99M | 26.46M |
| OtherCurrentLiabilities | 6.34M | |||
| CurrentDeferredLiabilities | 0.00 | 1.32M | 0.00 | 100.00K |
| CurrentDeferredRevenue | 0.00 | 1.32M | 0.00 | 100.00K |
| CurrentDebtAndCapitalLeaseObligation | 811.84K | 1.85M | 1.40M | 3.10M |
| CurrentCapitalLeaseObligation | 535.99K | 801.95K | 623.58K | 1.30M |
| CurrentDebt | 275.85K | 1.05M | 772.66K | 1.80M |
| OtherCurrentBorrowings | 1.80M | |||
| CurrentNotesPayable | 275.85K | 1.05M | 772.66K | 1.80M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.99M | 1.46M | 2.36M | |
| PayablesAndAccruedExpenses | 7.17M | 7.64M | 12.13M | 14.56M |
| CurrentAccruedExpenses | 4.99M | 5.23M | 3.50M | 4.78M |
| InterestPayable | 22.44K | 78.00K | 8.19K | 0.00 |
| Payables | 2.17M | 2.41M | 8.64M | 9.78M |
| OtherPayable | 479.25K | 1.46M | 4.91M | 5.10M |
| DuetoRelatedPartiesCurrent | 0.00 | 2.37K | ||
| TotalTaxPayable | 40.00K | 50.00K | 216.25K | |
| AccountsPayable | 1.69M | 945.93K | 3.68M | 4.46M |
| TotalAssets | 44.20M | 83.94M | 50.90M | 81.14M |
| TotalNonCurrentAssets | 20.40M | 25.03M | 28.81M | 30.95M |
| NonCurrentPrepaidAssets | 221.00K | 350.23K | 467.69K | 0.00 |
| NonCurrentDeferredAssets | 261.11K | 0.00 | ||
| NetPPE | 19.92M | 24.68M | 28.34M | 30.95M |
| AccumulatedDepreciation | -14.57M | -9.91M | -6.28M | -3.22M |
| GrossPPE | 34.50M | 34.60M | 34.62M | 34.17M |
| Leases | 7.06M | 9.30M | 9.30M | 5.70M |
| ConstructionInProgress | 0.00 | 308.32K | 4.61M | |
| OtherProperties | 15.90M | 14.36M | 14.09M | 14.07M |
| MachineryFurnitureEquipment | 11.53M | 10.94M | 10.92M | 9.79M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 23.79M | 58.91M | 22.10M | 50.19M |
| OtherCurrentAssets | 2.98M | 2.34M | 1.49M | |
| RestrictedCash | 0.00 | 6.34M | ||
| PrepaidAssets | 1.49M | 2.64M | ||
| Receivables | 54.95K | 0.00 | 5.56M | 8.01M |
| AccruedInterestReceivable | 54.95K | 0.00 | ||
| AccountsReceivable | 0.00 | 5.56M | 8.01M | |
| CashCashEquivalentsAndShortTermInvestments | 20.76M | 56.57M | 15.05M | 33.21M |
| OtherShortTermInvestments | 11.86M | 0.00 | ||
| CashAndCashEquivalents | 8.90M | 56.57M | 15.05M | 33.21M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -34.63M | -25.32M | -25.63M | -8.96M |
| RepurchaseOfCapitalStock | 0.00 | -5.52M | 0.00 | |
| RepaymentOfDebt | -1.42M | -1.16M | -2.42M | -1.30M |
| IssuanceOfDebt | 515.99K | 765.19K | 1.24M | 2.84M |
| IssuanceOfCapitalStock | 0.00 | 7.50M | 7.68M | 0.00 |
| CapitalExpenditure | -337.26K | -197.15K | -2.17M | -10.94M |
| InterestPaidSupplementalData | 373.95K | 245.48K | 293.39K | 294.46K |
| EndCashPosition | 8.90M | 56.57M | 15.05M | 39.55M |
| BeginningCashPosition | 56.57M | 15.05M | 39.55M | 12.61M |
| EffectOfExchangeRateChanges | -241.20K | 18.14K | 0.00 | |
| ChangesInCash | -47.43M | 41.50M | -24.50M | 26.93M |
| FinancingCashFlow | -1.17M | 66.77M | 1.05M | 35.89M |
| CashFlowFromContinuingFinancingActivities | -1.17M | 66.77M | 1.05M | 35.89M |
| NetOtherFinancingCharges | -286.04K | 34.34M | 34.34M | |
| ProceedsFromStockOptionExercised | 20.41K | 59.66M | 76.97K | 6.75K |
| NetPreferredStockIssuance | 0.00 | 7.50M | 0.00 | |
| PreferredStockIssuance | 0.00 | 7.50M | 0.00 | |
| NetCommonStockIssuance | 0.00 | 2.16M | 0.00 | |
| CommonStockPayments | 0.00 | -5.52M | 0.00 | |
| CommonStockIssuance | 0.00 | 7.68M | 0.00 | |
| NetIssuancePaymentsOfDebt | -907.00K | -390.44K | -1.19M | 1.54M |
| NetLongTermDebtIssuance | -907.00K | -390.44K | -1.19M | 1.54M |
| LongTermDebtPayments | -1.42M | -1.16M | -2.42M | -1.30M |
| LongTermDebtIssuance | 515.99K | 765.19K | 1.24M | 2.84M |
| InvestingCashFlow | -11.96M | -152.70K | -2.09M | -10.94M |
| CashFlowFromContinuingInvestingActivities | -11.96M | -152.70K | -2.09M | -10.94M |
| NetInvestmentPurchaseAndSale | -11.63M | 0.00 | ||
| SaleOfInvestment | 25.82M | 0.00 | ||
| PurchaseOfInvestment | -37.45M | 0.00 | ||
| NetPPEPurchaseAndSale | -337.26K | -152.70K | -2.09M | -10.94M |
| SaleOfPPE | 0.00 | 44.45K | 76.39K | 0.00 |
| PurchaseOfPPE | -337.26K | -197.15K | -2.17M | -10.94M |
| OperatingCashFlow | -34.29M | -25.12M | -23.46M | 1.99M |
| CashFlowFromContinuingOperatingActivities | -34.29M | -25.12M | -23.46M | 1.99M |
| ChangeInWorkingCapital | -2.30M | 2.33M | -237.57K | 11.68M |
| ChangeInOtherWorkingCapital | -1.35M | 1.71M | -100.00K | |
| ChangeInOtherCurrentAssets | 387.30K | 53.44K | -63.63K | |
| ChangeInPayablesAndAccruedExpense | -307.70K | -4.42M | -3.32M | 446.32K |
| ChangeInAccruedExpense | -1.23M | -1.71M | -2.54M | 3.38M |
| ChangeInPayable | 923.32K | -2.70M | -781.79K | -2.94M |
| ChangeInAccountPayable | 923.32K | -2.70M | -779.42K | -2.94M |
| ChangeInPrepaidAssets | -590.46K | -523.61K | 674.55K | -1.26M |
| ChangeInReceivables | -54.95K | 5.56M | 2.45M | 12.56M |
| ChangesInAccountReceivables | 0.00 | 5.56M | 2.45M | 12.56M |
| OtherNonCashItems | -237.09K | 3.71M | -32.21K | |
| StockBasedCompensation | 2.94M | 2.42M | 2.67M | 2.31M |
| DepreciationAmortizationDepletion | 4.79M | 3.75M | 3.29M | 1.65M |
| DepreciationAndAmortization | 4.79M | 3.75M | 3.29M | 1.65M |
| Depreciation | 4.79M | 3.75M | 3.29M | 1.65M |
| OperatingGainsLosses | -5.39M | 4.87M | -10.42M | 3.48M |
| GainLossOnInvestmentSecurities | -5.39M | 4.82M | -10.40M | 4.15M |
| GainLossOnSaleOfPPE | 0.00 | 44.49K | -15.80K | -5.49K |
| NetIncomeFromContinuingOperations | -34.11M | -42.19M | -18.74M | -17.14M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SABS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|